<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179632">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756418</url>
  </required_header>
  <id_info>
    <org_study_id>0476-396</org_study_id>
    <secondary_id>MK0476-396</secondary_id>
    <secondary_id>2008_027</secondary_id>
    <nct_id>NCT00756418</nct_id>
  </id_info>
  <brief_title>Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)</brief_title>
  <official_title>A Randomized Open-Label Comparative Study of Montelukast Versus Theophylline Added to Inhaled Corticosteroid in Pediatric Patients With Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A clinical study explores the safety and efficacy of montelukast and to compare the safety
      and efficacy of montelukast with those of theophylline in pediatric bronchial asthma
      patients when they are used in conjunction with inhaled steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of AM PEF over first 2 Weeks</measure>
    <time_frame>Over first 2 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>montelukast 5 mg QD 4-weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline 100 to 200 mg BID 4-weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric Bronchial Asthma Patients Aged 6 To 14 Years (At The Beginning Of The
             Treatment Period)

          -  The Severity Must Be Mild, Moderate Or Severe, Persistent Bronchial Asthma

          -  The Patient Must Have Symptoms That Can Be Used As Efficacy Variables (Such As
             Repeated Coughing And Mild Or Moderate Asthma Attacks) During The Observation Period,
             And Must Be Using Inhaled Steroids

        Exclusion Criteria:

          -  Patient Using Anti-Asthma Treatment Or Therapy Including corticosteroids Or Oral
             Anti-Allergic Drugs

          -  Patient With Complications That Will Impair The Judgment Of Efficacy Of This Drug

          -  Patient With Convulsive Disorders Such As Epilepsy Or Such A History

          -  Patient With Liver Disease, Renal Impairment, Heart Disease Or Such Other
             Complication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergol Int. 2006 Sep;55(3):287-93.</citation>
    <PMID>17075269</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 24, 2015</lastchanged_date>
  <firstreceived_date>September 19, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
